OncoMatch/Clinical Trials/NCT04594642
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
Is NCT04594642 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies AZD0486 IV for b-cell non hodgkin lymphoma.
Treatment: AZD0486 IV — This phase 1 study will investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity of AZD0486, a CD19 x CD3 T-cell engaging bispecific antibody, in subjects with B-cell non-Hodgkin lymphoma (B-NHL).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Biomarker criteria
Required: CD19 positive
Subject must have locally confirmed CD19 positivity (must be documented after time of progression from last CD19-targeted therapy, if received)
Disease stage
Required: Stage II, III, IV
Grade: 123a (who 2016)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: CD19 CAR T cell therapy
Exception: CAR T-naive subjects are allowed if they have declined, are considered ineligible for, or do not have timely access to CAR T cell therapies
CAR T-naive subjects are allowed if they have declined, are considered ineligible for, or do not have timely access to CAR T cell therapies.
Cannot have received: CD19 CAR T cell therapy
Subject received CD19 CAR T therapy within 3 months prior to first dose.
Cannot have received: peripheral autologous stem cell transplant
Subject has received a peripheral autologous stem cell transplant (SCT) within 12 weeks
Cannot have received: allogeneic stem cell transplant
an allogeneic SCT within 1 year of the first dose of study drug treatment
Cannot have received: stem cell transplant
Exception: requires ongoing immunosuppressive therapy
has received an SCT and requires ongoing immunosuppressive therapy
Lab requirements
Blood counts
anc ≥ 1000/mm3, platelets ≥ 50,000 mm3, hemoglobin ≥ 8.0 g/dl
Kidney function
egfr ≥ 50 ml/min
Liver function
total bilirubin <1.5x uln, ast/alt < 3xuln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Tampa, Florida
- Research Site · Louisville, Kentucky
- Research Site · New Brunswick, New Jersey
- Research Site · Charlotte, North Carolina
- Research Site · Columbus, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04594642 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CD19 CAR T cell therapy, CD19 CAR T cell therapy, peripheral autologous stem cell transplant disqualifies patients from enrollment.
Does this trial require CD19?
Yes, CD19 positive is a required biomarker for enrollment.
What disease stage is eligible?
Stage II or III or IV is required.
Is there an age limit?
Yes. Patients must be 130 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify